Last reviewed · How we verify
Combination Product: Nab-Paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Combination Product: Nab-Paclitaxel (Combination Product: Nab-Paclitaxel) — TransThera Sciences (Nanjing), Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Combination Product: Nab-Paclitaxel TARGET | Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Combination Product: Nab-Paclitaxel CI watch — RSS
- Combination Product: Nab-Paclitaxel CI watch — Atom
- Combination Product: Nab-Paclitaxel CI watch — JSON
- Combination Product: Nab-Paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). Combination Product: Nab-Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-product-nab-paclitaxel. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab